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ince  the  inclusion  of  Haemophilus  inﬂuenza  type  b  (Hib)
onjugate  vaccine  (HibCV)  into  childhood  immunization  pro-
rams,  there  has  been  virtual  elimination  of  Hib  meningitis
n  high-  and  low-income  countries.1,2 This  resulted  from
mmunization  of  young  children,  which  not  only  conferred
irect  protection  against  invasive  Hib  disease  among  immu-
ized  children,  but  also  indirect  protection  of  unvaccinated
ndividuals,  due  to  the  interruption  of  transmission  of  the
acterium  within  communities  through  targeted  vaccination
f  young  children.3 Subsequent  to  HibCV  immunization  of
hildren,  Streptococcus  pneumoniae  emerged  as  the  leading
ause  of  bacterial  meningitis  in  most  countries,  albeit  sec-
nd  to  Neisseria  meningitidis  (32%)  in  some  countries,  such
s  Brazil.4 The  study  by  Hirose  et  al.,  published  in  this  issue
f  the  Journal,  suggests  that  further  changes  in  the  epidemi-
logy  of  childhood  meningitis  in  Brazil  are  likely  to  occur,
ince  the  introduction  of  the  10-valent  polysaccharide-
rotein-D  protein  conjugate  vaccine  (PCV10)  into  the  public
mmunization  program  in  March  of  2010.5 Using  the  Noti-
able  Diseases  Information  System  on  reported  cases  of
neumococcal  meningitis  for  the  Brazilian  state  of  Paraná,
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n  the  incidence  of  pneumococcal  meningitis  and  a  76%
eduction  in  the  incidence  of  death  due  to  pneumococcal
eningitis  in  children  younger  than  2  years.  This  occurred
ithin  two-years  of  introducing  PCV10  into  the  public
mmunization  program  of  Brazil;  the  authors  performed  a
omparison  with  the  pre-PCV10  era.
Although  these  observations  are  encouraging,  it  is  impor-
ant  to  interpret  the  ﬁndings  in  the  context  of  the  limitations
nd  possible  biases  that  are  inherent  to  passive  reporting
ystems,  including  variability  in  completeness  and  accuracy
f  capture  of  cases  over  time.  This  could  inadvertently  bias
he  ﬁndings  from  ecological  studies  using  such  administra-
ive  databases,  either  through  overestimation  of  the  impact
f  PCV  (should  reporting  have  been  suboptimal  following  PCV
ntroduction)  or  underestimation  of  its  effect  (should  there
ave  been  enhanced  reporting  of  cases  in  the  post-PCV  era).
ne  way  of  addressing  this  limitation  is  to  analyse  for  other
iseases  recorded  in  such  systems,  which  are  less  likely  to
ave  been  affected  by  the  intervention  under  investigation
nd  which  themselves  are  not  subject  to  temporal  changes.
n  this  regard,  it  would  have  been  useful  to  analyse  the
rends  in  incidence  of  other  causes  of  bacterial  meningitis,
uch  as  Group  B Streptococcus  (GBS),  which  although  mainly
ffecting  infants  <  3  months  of  age,  is  expected  to  remain
argely  unchanged.6,7 Such  a  ‘‘dummy’’  analyses  would  help
o  verify  the  stability  in  documentation  of  bacterial  menin-
itis  cases  in  the  reporting  system.  Similarly,  reporting  on
he  trends  of  incidence  by  vaccine-serotype  and  non-vaccine
erotype  (excluding  those  for  which  there  could  be  cross-
er Editora Ltda. All rights reserved.
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protection  or  are  known  to  be  associated  with  temporal
variability)  would  further  strengthen  the  interpretation  of
the  current  results.  In  contrast,  trends  in  meningitis  due
to  Neisseria  meningitidis  would  have  been  less  useful  as  a
‘‘dummy’’  variable  analysis,  as  it  is  subject  to  natural  tem-
poral  changes  and  could  also  be  affected  by  introduction  of
vaccines  recently  developed  against  this  bacterium.
Also,  although  the  current  study  details  the  proportion
of  pneumococcal  meningitis  cases  that  were  due  to  the
PCV10-serotypes  prior  to  the  PCV10  era  (58%)  and  dur-
ing  the  PCV10-era  (46%),  the  results  were  not  analyzed
speciﬁcally  in  relation  to  vaccine  serotype-speciﬁc  changes
in  incidence  of  meningitis,  possibly  due  to  the  fact  that
serotyping  was  only  performed  in  <  50%  of  isolates.  Further-
more,  the  study  is  unlikely  to  have  had  sufﬁcient  number
of  cases  of  meningitis  by  individual  serotypes  to  determine
whether  there  was  uniform  protection  against  all  serotypes,
or  whether  the  changes  were  speciﬁc  to  some  serotypes,
such  as  1  and  5.  These  serotypes  could  undergo  natural
year-on-year  incidence  ﬂuctuation.  Serotype  1  in  particu-
lar  is  a  major  cause  of  pneumococcal  meningitis  in  some
settings;8 although  included  in  PCV10  (and  PCV13),  it  could
have  rapidly  declined  due  to  natural  ﬂuctuations  in  its  inci-
dence,  which  was  only  coincidentally  temporally  related  to
PCV  introduction.
As  such,  whilst  the  decline  in  incidence  of  pneumo-
coccal  meningitis  that  was  temporally  related  to  PCV10
childhood  immunization  in  this  ecological  study  is  promising,
the  results  need  to  be  corroborated  by  additional  vac-
cine  effectiveness  studies  in  the  same  setting.  Such  studies
have  recently  been  forthcoming  from  Brazil,  including  a
multi-centred  case-control  study  on  invasive  pneumococ-
cal  disease  (IPD)  that  included  meningitis  cases.9 In  the
latter  study,  Domingues  et  al.  reported  that  PCV10  immu-
nization  using  the  three  dose  primary  series  (at  2,  4,  and
6  months  of  age)  and  a  booster  dose  at  age  12  months  was
associated  with  a  84%  reduction  (95%  CI:  66-92)  in  PCV10
serotype  IPD  and  notably  also  a  78%  reduction  (95%  CI:
41-92)  in  vaccine-related  serotypes  (6A  and  19A),  whose
immunological  cross-reactivity  had  been  reported  from  ear-
lier  immunogenicity  studies.10 This  indicates  that  the  PCV10
formulation  effectively  prevented  IPD  due  to  at  least  12
serotypes,  including  serotype  19A  (VE:  82%;  95%  CI:  11-96).
Serotype  19A  previously  emerged  as  a  major  serotype  that
caused  ‘‘replacement  disease’’  following  the  introduction
of  the  7-valent  polysaccharide-CRM197 protein  conjugate
vaccine  (PCV7)  into  immunization  programs  of  some  high-
income  countries,  which  was  largely  due  to  clonal  expansion
of  pre-existing  antibiotic-resistant  strains.11 Additionally,
clonal  expansion  of  other  non-PCV7  serotypes,  including
serotypes  1,  3,  7F,  22F,  and  33F,  were  observed  in  United
Kingdom  following  PCV7  immunization.12 The  effectiveness
of  PCV10  against  IPD  is  further  corroborated  by  a  cluster
randomized  control  trial  of  PCV10  undertaken  in  Finland,  in
which  vaccine  efﬁcacy  was  100%  for  the  3+1  dosing  schedule
and  93%  for  a  two-dose  primary  series  followed  by  a  booster
dose.13
Despite  the  limitations  of  the  study  by  Hirose  et  al.,
the  results  are  nevertheless  consistent  with  the  impact
that  PCV7  childhood  immunization  had  on  vaccine-serotype
meningitis  in  high-income  countries.  A  recent  review  on  the
effect  of  PCV7  on  pneumococcal  meningitis  in  European
l
a
i
p109
nd  North  American  countries  demonstrated  reductions  of
accine  serotype  meningitis  of  59%  within  one  year  of  intro-
uction  in  the  United  States,  and  of  up  to  100%  in  some
ountries  among  the  age  groups  targeted  for  vaccination.14
n  addition,  many  studies  reported  a  decline  in  incidence
f  vaccine-serotype  meningitis  among  the  age  groups  that
ere  not  targeted  for  vaccination.  In  the  United  States,
his  decline  among  PCV  unvaccinated  age-groups  was  of
lightly  lower  magnitude  (59%  to  65%  reduction)  com-
ared  to  that  observed  in  children  younger  than  1  year
83%  reduction)  ten  years  following  PCV7  introduction.15
his  reﬂects  some  ongoing  transmission  of  the  vaccine-
erotypes  even  in  countries  such  as  the  United  States,
nd  possibly  a  lag  in  indirect  protection  materializing  rel-
tive  to  the  direct  effect  among  the  age  groups  targeted
or  vaccination.  Similarly  to  HibCV,  the  indirect  effect
f  PCV  immunization  of  children,  who  are  the  main  age
roup  reservoir  of  pneumococcal  colonization  and  source
f  transmission  in  communities,  is  related  to  vaccination
educing  their  risk  of  acquiring  vaccine-serotype  nasopha-
yngeal  colonization.16 Consequently,  there  is  interruption
f  the  transmission  of  vaccine-serotypes  in  the  commu-
ity  and  reduced  acquisition  of  these  serotypes  even  among
nvaccinated  individuals,  thus  protecting  them  from  devel-
ping  IPD  (including  meningitis).3 Although  the  study  by
irose  et  al.  did  not  analyze  the  effect  of  childhood  PCV10
mmunization  on  the  incidence  of  pneumococcal  meningitis
mong  PCV-unvaccinated  age  groups,  the  ﬁndings  by  Ham-
itt  et  al.,  from  Kenya,  support  that  PCV10  (similarly  to
CV7  and  PCV13)  result  in  indirect  community  protection
gainst  pneumococcal  colonization  (and  consequently  likely
gainst  disease).17
Despite  the  success  in  reducing  the  incidence  of  pneumo-
occal  meningitis,  it  remained  a  leading  cause  of  bacterial
eningitis  in  the  United  States  (58%)  seven  years  following
CV7  introduction,  albeit  being  second  to  GBS  in  those  <
8  years.7 Also,  the  case  fatality  proportion  of  pneumococ-
al  meningitis  has  remained  unchanged  in  the  United  States
nd  in  the  United  Kingdom  in  the  era  of  PCV  immunization
14%  to  16%),7,12,18 as  well  as  in  the  study  by  Hirose  et  al.,
hen  comparing  the  pre-PCV  (31%)  to  the  PCV-era  (19%,
 =  0.25).  Furthermore,  a  high  rate  (63%)  of  neurological
equelae  among  children  surviving  pneumococcal  menin-
itis  persists,  regardless  of  whether  it  was  due  to  PCV7
accine-serotypes.18 As  further  reductions  in  pneumococ-
al  meningitis  are  expected  since  the  transition  from  PCV7
o  the  PCV13  formulation  in  many  countries,  the  incidence
f  pneumococcal  meningitis  is  likely  to  decline  further  in
ountries  where  PCV13  (or  PCV10)  vaccination  has  been
idely  implemented.  This  change  is  already  being  observed
n  the  United  States,  within  one  year  of  transitioning  from
CV7  to  PCV13  for  immunization,  with  a  further  57%  reduc-
ion  observed  in  IPD  due  to  PCV13  serotypes  compared  to
he  era  of  PCV7  utilisation.19 The  reduction  in  pneumo-
occal  meningitis  was,  however,  lower  than  the  decrease
bserved  in  vaccine-serotype  bacteremia,  pneumonia,  and
astoiditis.19 With  the  further  decline  in  pneumococcal
eningitis,  it  is  expected  that  GBS  will  now  become  theeading  cause  of  bacterial  meningitis  in  the  United  States
mong  the  pediatric  population,  albeit  concentrated  in
nfants  younger  than  3  months.7 Although  a trivalent  GBS
olysaccharide  protein  conjugate  vaccine  is  currently  in
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210  
hase  II  clinical  studies,20 the  target  for  such  a  vaccine  is
he  immunization  of  pregnant  women,  aimed  at  increasing
he  transplacental  transfer  of  capsular  antibody  to  the  fetus;
his  is  subsequently  expected  to  protect  young  infant  against
BS  (group  B  streptococcal)  meningitis  and  other  invasive
BS  disease.21
Although  pneumococcal  meningitis  is  among  the  least
ommon  forms  of  severe  pneumococcal  disease,  it  remains
 disease  with  high  proportions  of  fatality  and  neurological
equelae.  The  PCV  vaccines  have  now  been  established  to
revent  vaccine-serotype  meningitis.  Considering  the  higher
ncidence  of  pneumococcal  disease  and  much  higher  mor-
ality  associated  with  pneumococcal  meningitis  (35%)  in
hildren  from  low-income  countries,22 expediting  the  intro-
uction  of  PCV  into  all  low-middle  income  countries  in  a
ost-effective  and  sustainable  manner  should  be  prioritized.
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